Silvia Marsoni Silvia Marsoni LabItaly

Silvia Marsoni Candilo is a prominent figure in the field of cancer research and development. She has been active in cancer research for over 30 years, focusing on drug development and clinical trial methodology. Her work has been instrumental in designing and conducting pivotal large-scale trials, particularly in colon and lung cancer. Marsoni has also been involved in early drug development and the SENDO Foundation, which organized early phase trials for novel cytotoxic, targeted, and epigenetic drugs. Her research has led to significant achievements, including the establishment of trabectedin as a new drug for ovarian cancer. Marsoni's commitment to precision medicine and the development of predictive biomarkers in colon and lung cancers has been a driving force in her career.